Access the full text.
Sign up today, get DeepDyve free for 14 days.
Daniel Osipovitch, Andrew Parker, Christabell Makokha, J. Desrosiers, W. Kett, L. Moise, C. Bailey-Kellogg, K. Griswold (2012)
Design and analysis of immune-evading enzymes for ADEPT therapy.Protein engineering, design & selection : PEDS, 25 10
T. Jones, R. Hart, P. Popovich (2005)
Molecular Control of Physiological and Pathological T-Cell Recruitment after Mouse Spinal Cord InjuryThe Journal of Neuroscience, 25
E. Trombetta, I. Mellman (2005)
Cell biology of antigen processing in vitro and in vivo.Annual review of immunology, 23
P. McCaldon, P. Argos (1988)
Oligopeptide biases in protein sequences and their use in predicting protein coding regions in nucleotide sequencesProteins: Structure, 4
Anne Groot, D. Scott (2007)
Immunogenicity of protein therapeutics.Trends in immunology, 28 11
J. Cizeau, Danielle Grenkow, Jennifer Brown, J. Entwistle, G. Macdonald (2009)
Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin BouganinJournal of Immunotherapy, 32
H. Bui, J. Sidney, Bjoern Peters, M. Sathiamurthy, Asabe Sinichi, Kelly-Anne Purton, B. Mothé, F. Chisari, D. Watkins, A. Sette (2005)
Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applicationsImmunogenetics, 57
J. Hill, Dequn Wang, A. Jevnikar, E. Cairns, D. Bell (2002)
The relationship between predicted peptide–MHC class II affinity and T-cell activation in a HLA-DRβ1*0401 transgenic mouse modelArthritis Research & Therapy, 5
L. Moise, Chang Song, W. Martin, Ryan Tassone, Anne Groot, D. Scott (2012)
Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.Clinical immunology, 142 3
M. Barbosa (2011)
Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters.Drug discovery today, 16 7-8
Peng Wang, J. Sidney, Courtney Dow, B. Mothé, A. Sette, Bjoern Peters (2008)
A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus ApproachPLoS Computational Biology, 4
H. Singh, Gajendra Raghava (2001)
ProPred: prediction of HLA-DR binding sitesBioinformatics, 17 12
L. Perry, T. Jones, M. Baker (2008)
New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical DevelopmentDrugs in R & D, 9
F. Kern, G. Lipira, J. Gratama, F. Manca, M. Roederer (2005)
Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer.Trends in immunology, 26 9
Regina Salvat, L. Moise, C. Bailey-Kellogg, K. Griswold (2014)
A high throughput MHC II binding assay for quantitative analysis of peptide epitopes.Journal of visualized experiments : JoVE, 85
Andrew Parker, K. Griswold, C. Bailey-Kellogg (2011)
Optimization of Therapeutic proteins to Delete T-Cell epitopes while Maintaining Beneficial Residue InteractionsJournal of bioinformatics and computational biology, 9 2
W. Stemmer, A. Crameri, Kim Ha, T. Brennan, H. Heyneker (1995)
Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides.Gene, 164 1
H Schellekens (2007)
Immunogenicity of protein therapeutics, or how to make antibodies without T-cellsInflamm Res, 56
J. Cantor, T. Yoo, Aakanksha Dixit, B. Iverson, T. Forsthuber, G. Georgiou (2011)
Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral driftProceedings of the National Academy of Sciences, 108
Ji Wan, Wen Liu, Qiqi Xu, Yongliang Ren, D. Flower, Tongbin Li (2006)
SVRMHC prediction server for MHC-binding peptidesBMC Bioinformatics, 7
Jason Weaver, A. Sant (2009)
Understanding the focused CD4 T cell response to antigen and pathogenic organismsImmunologic Research, 45
Inga Sandler, Nitzan Zigdon, Efrat, Levy Aharoni
Cellular and Molecular Life Sciences the Functional Importance of Co‑evolving Residues in Proteins
W. Delano (2002)
The PyMOL Molecular Graphics System
V. Yeung, Judy Chang, Jeffrey Miller, C. Barnett, M. Stickler, F. Harding (2004)
Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant EpitopeThe Journal of Immunology, 172
S. Southwood, J. Sidney, A. Kondo, M. Guercio, E. Appella, S. Hoffman, R. Kubo, R. Chesnut, H. Grey, A. Sette (1998)
Several common HLA-DR types share largely overlapping peptide binding repertoires.Journal of immunology, 160 7
Anne Groot, W. Martin (2009)
Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics.Clinical immunology, 131 2
H. Schellekens (2005)
Factors influencing the immunogenicity of therapeutic proteins.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 20 Suppl 6
A. Groot, Paul Knopf, W. Martin (2005)
De-immunization of therapeutic proteins by T-cell epitope modification.Developments in biologicals, 122
G. Pira, F. Ivaldi, P. Moretti, F. Manca (2010)
High Throughput T Epitope Mapping and Vaccine DevelopmentJournal of Biomedicine and Biotechnology, 2010
M. Onda (2009)
Reducing the immunogenicity of protein therapeutics.Current drug targets, 10 2
R. Mazor, A. Vassall, Jaime Eberle, R. Beers, John Weldon, D. Venzon, K. Tsang, I. Benhar, I. Pastan (2012)
Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin AProceedings of the National Academy of Sciences, 109
M. Nielsen, C. Lundegaard, O. Lund (2007)
Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment methodBMC Bioinformatics, 8
P. Warmerdam, S. Plaisance, K. Vanderlick, P. Vandervoort, K. Brepoels, D. Collen, M. Maeyer (2002)
Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer ModelingThrombosis and Haemostasis, 87
Andrew Parker, K. Griswold, C. Bailey-Kellogg (2012)
Structure-Guided Deimmunization of Therapeutic Proteins
S. Lee (2010)
Implications of available design space for identification of non-immunogenic protein therapeuticsBiomedical Microdevices, 12
M. Nielsen, S. Justesen, O. Lund, C. Lundegaard, S. Buus (2010)
NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedureImmunome Research, 6
Yoonjoo Choi, K. Griswold, C. Bailey-Kellogg (2013)
Structure‐based redesign of proteins for minimal T‐cell epitope contentJournal of Computational Chemistry, 34
M. Baker, Helen Reynolds, B. Lumicisi, Christine Bryson (2010)
Immunogenicity of protein therapeutics: The key causes, consequences and challenges.Self/nonself, 1 4
E. Koren, A. Groot, V. Jawa, K. Beck, T. Boone, Daniel Rivera, L. Li, D. Mytych, M. Koscec, Dohan Weeraratne, S. Swanson, W. Martin (2007)
Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein.Clinical immunology, 124 1
S. Tangri, B. Mothé, Julie Eisenbraun, J. Sidney, S. Southwood, Kristen Briggs, J. Zinckgraf, P. Bilsel, M. Newman, R. Chesnut, C. Licalsi, A. Sette (2005)
Rationally Engineered Therapeutic Proteins with Reduced ImmunogenicityThe Journal of Immunology, 174
I Sandler, N Zigdon, E Levy, A Aharoni (2014)
The functional importance of co-evolving residues in proteinsCell Mol Life Sci, 71
AS Parker, W Zheng, KE Griswold, C Bailey-Kellogg (2010)
Optimization algorithms for functional deimmunization of therapeutic proteinsBMC Bioinform, 11
F. Harding, Amy Liu, M. Stickler, O. Razo, R. Chin, Nargol Faravashi, Wendy Viola, T. Graycar, V. Yeung, W. Aehle, D. Meijer, S. Wong, M. Rashid, A. Valdes, V. Schellenberger (2005)
A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapyMolecular Cancer Therapeutics, 4
P. Guan, I. Doytchinova, C. Zygouri, D. Flower (2003)
MHCPred: bringing a quantitative dimension to the online prediction of MHC binding.Applied bioinformatics, 2 1
Biotherapeutics are subject to immune surveillance within the body, and anti-biotherapeutic immune responses can compromise drug efficacy and patient safety. Initial development of targeted antidrug immune memory is coordinated by T cell recognition of immunogenic subsequences, termed “T cell epitopes.” Biotherapeutics may therefore be deimmunized by mutating key residues within cognate epitopes, but there exist complex trade-offs between immunogenicity, mutational load, and protein structure–function. Here, a protein deimmunization algorithm has been applied to P99 beta-lactamase, a component of antibody-directed enzyme prodrug therapies. The algorithm, integer programming for immunogenic proteins, seamlessly integrates computational prediction of T cell epitopes with both 1- and 2-body sequence potentials that assess protein tolerance to epitope-deleting mutations. Compared to previously deimmunized P99 variants, which bore only one or two mutations, the enzymes designed here contain 4–5 widely distributed substitutions. As a result, they exhibit broad reductions in major histocompatibility complex recognition. Despite their high mutational loads and markedly reduced immunoreactivity, all eight engineered variants possessed wild-type or better catalytic activity. Thus, the protein design algorithm is able to disrupt broadly distributed epitopes while maintaining protein function. As a result, this computational tool may prove useful in expanding the repertoire of next-generation biotherapeutics.
Cellular and Molecular Life Sciences – Springer Journals
Published: Jun 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.